Global IVIG Market Report: 2013 Edition

Date: July 26, 2013
Pages: 60
US$ 800.00
Publisher: Koncept Analytics
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G9A08944993EN

Download PDF Leaflet

Global IVIG Market Report: 2013 Edition
With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to changing lifestyle and continuously changing surroundings, blood plasma industry’s growth is augmented, especially in the segment of immunoglobulins. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.

Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobulins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. IgG is naturally manufactured by plasma cells in human body. IgG antibody, also known as immunoglobulin-G is a large Y-shaped protein employed by the body’s immune system for neutralizing foreign substances like viruses and bacteria.

Intravenous immunoglobulin (IVIG) is a blood plasma derivative administered intravenously. It comprises of pooled, polyvalent, IgG (immunoglobulin (antibody) G) extracted from the plasma of more than one thousand blood donors. The very blood plasma derivative is deployed mainly in the treatment of autoimmune disorders, immune deficiencies and acute infections. IVIG has been the key factor to drive the growth of plasma products industry. The demand for IVIG has been growing on account of its increased usage in the treatment of primary immunodeficiency as well as newer neurological indications.

The present report offers an analysis of the global IVIG market with a special focus on the IVIG market of the US. The market is characterized by fast pace developments in the clinical technology and testing methodology. Despite challenges like stringent regulations and high cost of treatment, the global IVIG market is all set to witness high growth in the coming years as a result of growing ageing population, increasing number of patients with bleeding disorder, and rising health expenditure. Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global IVIG plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, and Grifols.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables, and tests.

1.1 Components of Blood Plasma
1.2 Collection and Extraction of Plasma
  1.2.1 Plasma Collection
  1.2.2 Plasma Extraction
  1.2.3 Plasma Fractionation Yield
1.3 Immunoglobulins: Intravenous immunoglobulin (IVIG)
  1.3.1 IVIG’s Action Mechanism
  1.3.2 IVIG Dosage and Administration


2.1 Global Blood Plasma Market
  Market Value
  Market Segmentation
2.2 Global IVIG Market
    Market Value
    Demand & Supply
    Regional Breakdown
  2.2.1 IVIG Market of the US
    Market Value
    Price Trend


3.1 Industry Trends and Developments
  3.1.1 Reimbursement
3.2 Growth Drivers
  3.2.1 Rising Healthcare Expenditure
  3.2.2 Higher Spending on Medicines
  3.2.3 Rising Demand for Better Healthcare Options
  3.2.4 Launch of NMEs (New Molecular Entities)
3.3 Challenges
  3.3.1 Increasing Regulation in Plasma-collection Industry
  3.3.2 Mounting Price Pressure
  3.3.3 Constrained Plasma Fractionation Capacity
  3.3.4 Misdiagnosis of the Disease


4.1 Immunoglobulins’ Market Contention
  4.1.1 IVIG Market of Europe
  4.1.2 IVIG Market of North America
  4.1.3 IVIG Market of the US


5.1 Baxter International Inc.
  5.1.1 Business Overview
  5.1.2 Financial Overview
  5.1.3 Business Strategies
    Advancing the Core Portfolio Globally
    Expansion of Product Portfolio
5.2 Grifols
  5.2.1 Business Overview
  5.2.2 Financial Overview
  5.2.3 Business Strategies
    Expansion in Other Regions
    Growth through Acquisitions
5.3 CSL Limited
  5.3.1 Business Overview
  5.3.2 Financial Overview
  5.3.3 Business Strategies
    Focus on R&D
    Expanding Product Portfolio


6.1 Market Forecast
6.2 Forecast Methodology
  6.2.1 Dependent and Independent Variables
  6.2.2 Correlation Analysis
  6.2.3 Regression Analysis


Plasma Extraction from Donated Blood (Recovered Plasma)
Plasmapheresis (Source Plasma)
Global Blood Plasma Market (2000-2011)
Global Plasma Market Share by Product (2011)
Global IVIG Market Size (2004-2012)
Global IVIG Demand and Supply (2007-2012E)
IVIG Market Volume by Region (2005, 2008 and 2011)
Global IVIG Market Share by Geography (2011)
IVIG Use by Indication
Sales of IVIG in the US (2001-2012)
Lyophilised and Liquid IVIG Average Pricing in the US (March 2007-March 2013)
Global Healthcare Spending (2005-2015E)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan’s Spending on Medicine (2007-2016E)
Biotechnology Therapeutics Under Development (2011)
Global Plasma Market Share by Company (2011)
Global IVIG Market Share (2012)
Pricing of Leading IVIG Products (June 2009-June 2013)
Capacity Expansion Plans of the Key Industry Players (2012 and 2016E)
Europe’s IVIG Market Share (2011)
North America’s IVIG Market Share (2011)
The US IVIG Market (2011)
The US IG Sales Share by Value (2012)
Baxter’s Revenue by Business Segments (2012)
Baxter’s Revenues and Net Income (2008-2012)
Grifols Revenue Share by Business Segments (2012)
Grifols’ Revenues & Net Profit (2008-2012)
CSL’s Revenue Share by Major Products (2011-12)
CSL’s Revenues and Net Profit (2008/09-2011/12)
Global IVIG Market Forecast (2011-2015F)


Constituents of Blood Plasma
Recovered plasma vs. Source plasma
Output per Liter of Plasma
Breakdown of US IVIG usage by patient share (%) and volume share (%) by indication
Breakdown of US SCIG and IVIG usage by volume share (FY12)
US Centre for Medicare and Medicaid (CMS) Reimbursement
Patients Worldwide Waiting for Better Treatment Options (2011)
Global Availability of NMEs (2011)
IVIG Product Characteristics
Dependent & Independent Variables (2007-2011)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
Skip to top

Competitor Analysis: Anti-Infective Antibodies US$ 1,086.00 Nov, 2011 · 160 pages
Octapharma AG - Strategic SWOT Analysis Review US$ 125.00 Jul, 2017 · 29 pages
Intravenous (IV) Solutions: Market Research Report US$ 4,800.00 Aug, 2011 · 274 pages

Ask Your Question

Global IVIG Market Report: 2013 Edition
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: